Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12616MR)

This product GTTS-WQ12616MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer, Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12616MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11069MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ9447MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ6059MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ6167MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ11369MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ9066MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ6193MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ11448MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-9447
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW